Massive blood transfusion for trauma

Publisher Website
Google Scholar
Abstract
Massive blood transfusion saves the lives of thousands of severely injured patients each year, but it does so in the context of the evolving epidemiology of injury, of trauma centers and trauma systems, and of blood safety and new technologies for hemorrhage control. This article reviews recent knowledge and advances that impact on the use and effectiveness of massive transfusion. Injury is rapidly becoming the second leading cause of death in the world. These deaths are highly preventable with social and engineering controls and good trauma care. Massive transfusion is readily available, safe, effective, and cheap in the context of modern trauma center care. However, aged blood products can cause transfusion-related acute lung injury, and better blood storage systems are under development. Recent work has improved understanding of the coagulopathy associated with acidosis and provided guidance for limiting dilutional coagulopathy. Nevertheless, massive transfusion always leads to coagulopathy and so is at best an adjunct to good surgical care. Better drugs and devices for hemorrhage control, such as recombinant activated factor VII and hemostatic bandages, are in development. Injury is a major public health and medical system problem. Progress in basic science, clinical care, and the development of better hemorrhage control devices are all improving outcome for massively transfused patients. Investment in trauma care and supporting blood supply systems is highly cost effective.

This publication has 45 references indexed in Scilit: